バキスゼブリア Oxford/Astra Zeneca COVID-19 vaccine, AZD1222


Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
 Ramasamy MN, Minassian AM, Ewer KJ, et al. 〔Lancet. 2021 Dec 19;396(10267):1979-1993〕(査読済み)


Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
 Voysey M, Clemens SAC, Madhi SA, et al. 〔Lancet. 2021 Jan 9;397(10269):99-111〕(査読済み)


Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
 Voysey M, Costa Clemens SA, Madhi SA, et al. 〔Lancet. 2021 Mar 6;397(10277):881-891〕(査読済み)


Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
 Barrett JR, Belij-Rammerstorfer S, Dold C, et al. 〔Nat Med. 2021 Feb;27(2):279-288〕(査読済み)


T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
 Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. 〔Nat Med. 2021 Feb;27(2):270-278〕(査読済み)


Efficacy of the ChAdOx1 nCoV-19 COVID-19 Vaccine against the B.1.351 Variant
 Madhi SA, Baillie V, Cutland CL, et al. 〔N Engl J Med. 2021 May 20;384(20):1885-1898〕(査読済み)


Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
 Emary KRW, Golubchik T, Aley PK, et al. 〔Lancet. 2021 Apr 10;397(10282):1351-1362〕(査読済み)


Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination (BRIEF REPORT)
 Schultz NH, Sørvoll IH, Michelsen AE, et al. 〔N Engl J Med. 2021 Jun 3;384(22):2124-2130〕(査読済み)


Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccinatione
 Greinacher A, Thiele T, Warkentin TE, et al. 〔N Engl J Med. 2021 Jun 3;384(22):2092-2101〕(査読済み)


Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
 Scully M, Singh D, Lown R, et al. 〔N Engl J Med. 2021 Jun 10;384(23):2202-2211〕(査読済み)


An observational study to identify the prevalence of thrombocytopenia and anti‐PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination (BRIEF REPORT)
 Sørvoll IH, Horvei KD, Ernstsen SL, et al. 〔J Thromb Haemost. 2021 Apr 28〕(査読済み)


Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study
 Pottegård A, Lund LC, Karlstad Ø, et al. 〔BMJ. 2021 May 5;373:n1114〕(査読済み)